Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Hims & Hers’

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Barchart

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

MarketBeat

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!

Barchart

Novo Nordisk drops lawsuit over weight loss medications, enters collaboration with online pharmacy

The news sent shares of Hims & Hers Health Inc. soaring by more than 40% in Monday morning trading

The Independent UK

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.

MarketBeat

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Super Bowl ads try to overcome tough times with health, caring and the usual laughs

At a difficult time for America, Super Bowl advertisers are asking viewers to take care of themselves and others — and maybe even crack a smile

The Independent UK

US health company launches weight-loss pill that Novo Nordisk calls an 'untested knockoff'

The American telehealth company announced the launch of a compounded weight-loss pill for €41, drawing criticism from Novo Nordisk, the Danish company behind the weight-loss drug Wegovy, which called the product an “untested knockoff.”

Euronews

Hims and Hers Super Bowl ad highlights 'uncomfortable truth' about elite healthcare for the rich and 'broken' system for the rest

The company is putting wealth inequality center stage as millions are expected to drop their Obamacare plans.

Fortune

What's Going On With Shares Of Hims & Hers Health Thursday?

Shares of Hims Hers Health, Inc. (NASDAQ:HIMS) are trending Thursday morning. The San Francisco-based telehealth company announced an international expansion.

Benzinga

Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing

Hims Hers Health, Inc. (NYSE:HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.

Benzinga

Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results

Hims & Hers Health delivered a mixed earnings report and announced a potential Wegovy partnership with Novo Nordisk; the downside risk to HIMS stock looks low.

MarketBeat

Hims & Hers Short Interest Nears All-Time High, Buy The Dip?

Hims & Hers stock is falling well off its 52-week highs, as bears lean on the CEO's scheduled sale that just took place, though it might be a mistake.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You?

Insider selling tests investor confidence as Hims & Hers faces valuation pressure and shifting GLP-1 momentum.

Benzinga

Trump's Weight-Loss Drug Push May Put These ETFs On A Diet

The weight-loss industry that fueled one of Wall Street’s most popular ETF themes may finally be going on a crash diet.

Benzinga

Why Hims & Hers Health Shares Are Sliding Friday

Shares of Hims Hers Health Inc (NYSE:HIMS) are trading lower Friday morning after comments from President Donald Trump indicated that he expects the prices of popular weight-loss drugs to decrease. Here’s what investors need to know.

Benzinga

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'

Shares of Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are going to come down in price.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem

Hims Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this time is not another flashy partnership — it's a rally built from within.

Benzinga

Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today

Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31. The SP 500 added 0.4% to 6,671.06, while the Nasdaq climbed nearly 0.7% to 22,670.08.These are the top stocks that gained the attention of retail traders and investors through the day: Hims Hers…

Benzinga

Investors Are Buying Hims & Hers Health Stock Following Wednesday's Platform Expansion Announcement

Hims Hers Health Inc (NYSE:HIMS) shares are trading higher Wednesday following the company’s launch of a new menopause and perimenopause care specialty on its Hers platform.

Thousandaire

9 Startups Nobody Talks About That Are Flying Under the Radar—and Raking In Millions

While flashy unicorns like OpenAI and SpaceX dominate headlines, dozens of smaller startups are quietly turning profits and changing industries without the hype. These hidden players focus on niche markets, sustainable models, and loyal customers rather than viral buzz. Many are already generating millions annually while staying out of the…

Barchart

HIMS Stock Just Got Rocked (Again) By the FDA. This Analyst Still Thinks Hims & Hers Can Surge 50%.

Despite a sharp selloff after the latest FDA warning, Hims & Hers continues to post triple-digit annual gains and strong revenue growth, with at least one analyst projecting a 50% upside.

MarketBeat

Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy

Hims & Hers Health posted 73% revenue growth and 31% more subscribers in Q2. With analyst targets hitting $68, is now the time to buy HIMS?

Benzinga

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds

Oscar Health Inc (NYSE:OSCR) just became one of Wall Street's buzziest policy trades. With ACA (Affordable Care Act) subsidy chatter swirling ahead of a possible government shutdown, the tech-driven insurer is drawing Hims Hers Health Inc (NYSE:HIMS) style moonshot comparisons — and short sellers may be sitting on a powder…

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.